Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ARIEL ANTEZANA ANTEZANA

NPI
1962737080
CMS profile
1379200
Location
ALEXANDRIA, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$17,805.39

265 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 3 of 6; records 101–150 of 265 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ARIEL ANTEZANA ANTEZANA

NPI 1962737080 · CMS profile ID 1379200

ALEXANDRIA, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 6; records 101–150 of 265 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1962737080?year=2025&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ARIEL ANTEZANA ANTEZANA, NPI 1962737080, CMS profile ID 1379200. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 6; records 101–150 of 265 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1962737080?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). ARIEL ANTEZANA ANTEZANA, NPI 1962737080, CMS profile ID 1379200. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 6; records 101–150 of 265 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1962737080?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
ARIEL ANTEZANA ANTEZANA, NPI 1962737080, CMS profile ID 1379200, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 6; records 101–150 of 265 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1962737080?year=2025&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

265 matching records · $17,805.39 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 265 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 265.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Neurocrine BioSciences, Inc. $21.1708/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1243021253 CMS
Neurocrine BioSciences, Inc. $2.4308/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1243058277 CMS
Neurocrine BioSciences, Inc. $0.5208/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1243059771 CMS
SK Life Science, Inc. $27.1708/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1252288905 CMS
ACADIA Pharmaceuticals Inc $17.1907/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247765479 CMS
ABBVIE INC. $20.1307/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201423033 CMS
Lundbeck LLC $14.5707/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251764718 CMS
Lilly USA, LLC $25.3807/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186517211 CMS
Neurocrine BioSciences, Inc. $1.0907/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1243059347 CMS
GENZYME CORPORATION $30.2207/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233529165 CMS
Neurocrine BioSciences, Inc. $11.9207/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1243048011 CMS
UCB, Inc. $26.2107/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224628598 CMS
ACADIA Pharmaceuticals Inc $23.0007/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247765475 CMS
ACADIA Pharmaceuticals Inc $2.1407/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247765477 CMS
ABBVIE INC. $13.7207/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201423029 CMS
ABBVIE INC. $5.3307/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201423031 CMS
UCB, Inc. $29.3707/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224628596 CMS
ABBVIE INC. $5.3207/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201423027 CMS
Genentech USA, Inc. $24.4007/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211495646 CMS
TG Therapeutics, Inc. $112.2307/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226207929 CMS
ABBVIE INC. $11.8807/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201423025 CMS
Eisai Inc. $18.7907/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244462735 CMS
Merz Pharmaceuticals, LLC $29.2607/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232556589 CMS
Biogen, Inc. $18.7907/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208367077 CMS
ABBVIE INC. $5.4107/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201423023 CMS
Biogen, Inc. $20.4107/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208394369 CMS
PFIZER INC. $17.5607/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229530059 CMS
Amneal Pharmaceuticals LLC $15.8107/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1220526861 CMS
Otsuka America Pharmaceutical, Inc. $11.4407/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227282535 CMS
UCB, Inc. $27.9607/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224628594 CMS
ABBVIE INC. $4.3907/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201423021 CMS
EMD Serono, Inc. $19.5407/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236922299 CMS
Janssen Biotech, Inc. $15.3707/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174560365 CMS
ABBVIE INC. $15.6906/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201423019 CMS
TG Therapeutics, Inc. $28.4706/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226207682 CMS
Neurocrine BioSciences, Inc. $12.7906/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1243047205 CMS
Neurocrine BioSciences, Inc. $5.1106/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1243055713 CMS
ARGENX US, INC. $20.6006/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240446578 CMS
ACADIA Pharmaceuticals Inc $18.6506/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247765473 CMS
Otsuka America Pharmaceutical, Inc. $27.9306/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227282532 CMS
SK Life Science, Inc. $21.6106/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1252288889 CMS
ACADIA Pharmaceuticals Inc $1.7506/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247765471 CMS
PFIZER INC. $5.1006/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229438620 CMS
Eisai Inc. $21.8106/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244462732 CMS
JAZZ PHARMACEUTICALS INC. $19.4906/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234337661 CMS
ABBVIE INC. $12.2206/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201423017 CMS
Novartis Pharmaceuticals Corporation $90.3906/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200005514 CMS
ABBVIE INC. $11.0006/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201423015 CMS
ABBVIE INC. $5.3206/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201423013 CMS
Genentech USA, Inc. $21.3906/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211495642 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $54,408.44 256
PY2020 $47,430.29 245
PY2021 $43,857.69 360
PY2022 $44,786.06 321
PY2023 $18,802.47 257
PY2024 $25,632.18 289
PY2025 $17,805.39 265

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $604,180.00 43
PY2024 Principal investigator $418,379.46 23
PY2023 Principal investigator $313,544.14 28
PY2022 Principal investigator $268,114.49 24
PY2021 Principal investigator $280,062.73 16
PY2020 Principal investigator $254,469.49 26
PY2019 Principal investigator $139,236.86 38

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

43 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 GENZYME CORPORATION $5,650.00 12/22/2025 Non-covered Recipient Entity
Investigator Research Network Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226083564
Principal investigator 1 GENZYME CORPORATION $1,680.50 12/22/2025 Non-covered Recipient Entity
Investigator Research Network Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226083567
Principal investigator 1 GENZYME CORPORATION $11,080.00 12/22/2025 Non-covered Recipient Entity
Investigator Research Network Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226083572
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,579.68 12/22/2025 Non-covered Recipient Entity
NEURO MEDIAL CLINIC OF CENTRAL LOUISIANA
A Pilot Open-Label, Randomized, Multi-Center, Parall el-Arm, of Acute vs Delay Ofatumumab Treatment d uring an Acute Multiple Sclerosis Relapse No dispute reported 06/30/2026 1190307155
Principal investigator 1 SANOFI US SERVICES INC. $12,756.20 12/22/2025 Non-covered Recipient Entity
Investigator Research Network Llc
A Phase 3, Doubleblind, Placebocontrolled Study Evaluating Efficacy and Safety of Riliprubart in Participants With Refractory Chronic Inflammatory Demyelinating Polyneuropathy No dispute reported 06/30/2026 1226083576
Principal investigator 1 GENZYME CORPORATION $6,472.25 12/08/2025 Non-covered Recipient Entity
Investigator Research Network Llc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226083538
Principal investigator 1 GENZYME CORPORATION $3,650.00 12/08/2025 Non-covered Recipient Entity
Investigator Research Network Llc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226083542
Principal investigator 1 Genentech, Inc. $5,593.00 12/02/2025 Non-covered Recipient Entity
INTERSPOND LLC
OCARINA I No dispute reported 06/30/2026 1211617257
Principal investigator 1 Genentech, Inc. $4,207.50 12/02/2025 Non-covered Recipient Entity
INTERSPOND LLC
OCARINA I No dispute reported 06/30/2026 1211617262
Principal investigator 1 Genentech, Inc. $2,002.00 12/02/2025 Non-covered Recipient Entity
INTERSPOND LLC
OCARINA I No dispute reported 06/30/2026 1211617267
Principal investigator 1 Genentech, Inc. $3,521.00 11/20/2025 Non-covered Recipient Entity
INTERSPOND LLC
OCARINA I No dispute reported 06/30/2026 1211617253
Principal investigator 1 GENZYME CORPORATION $8,608.00 11/17/2025 Non-covered Recipient Entity
Investigator Research Network Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226083524
Principal investigator 1 Novartis Pharmaceuticals Corporation $53,261.74 11/13/2025 Non-covered Recipient Entity
NEURO MEDIAL CLINIC OF CENTRAL LOUISIANA
A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light No dispute reported 06/30/2026 1190307159
Principal investigator 1 Novartis Pharmaceuticals Corporation $26,993.70 10/27/2025 Non-covered Recipient Entity
NEURO MEDIAL CLINIC OF CENTRAL LOUISIANA
A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light No dispute reported 06/30/2026 1190307157
Principal investigator 1 Genentech, Inc. $5,000.00 10/24/2025 Non-covered Recipient Entity
INTERSPOND LLC
OCARINA I No dispute reported 06/30/2026 1211617249
Principal investigator 1 GENZYME CORPORATION $3,531.00 09/29/2025 Non-covered Recipient Entity
Investigator Research Network Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226083483
Principal investigator 1 Genentech, Inc. $1,300.00 09/22/2025 Non-covered Recipient Entity
INTERSPOND LLC
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211617233
Principal investigator 1 Roche Products Limited $934.48 08/21/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211617151
Principal investigator 1 Genentech, Inc. $1,697.00 08/20/2025 Non-covered Recipient Entity
INTERSPOND LLC
OCARINA I No dispute reported 06/30/2026 1211617237
Principal investigator 1 Genentech, Inc. $2,250.00 08/20/2025 Non-covered Recipient Entity
INTERSPOND LLC
OCARINA I No dispute reported 06/30/2026 1211617246
Principal investigator 1 SANOFI US SERVICES INC. $1,800.00 08/04/2025 Non-covered Recipient Entity
Investigator Research Network Llc
A Phase 3, Doubleblind, Placebocontrolled Study Evaluating Efficacy and Safety of Riliprubart in Participants With Refractory Chronic Inflammatory Demyelinating Polyneuropathy No dispute reported 06/30/2026 1226083454
Principal investigator 1 Genentech, Inc. $942.00 07/29/2025 Non-covered Recipient Entity
INTERSPOND LLC
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211617219
Principal investigator 1 GENZYME CORPORATION $12,929.00 07/28/2025 Non-covered Recipient Entity
Investigator Research Network Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226083450
Principal investigator 1 GENZYME CORPORATION $4,238.00 07/21/2025 Non-covered Recipient Entity
Investigator Research Network Llc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226083437
Principal investigator 1 Roche Products Limited $436.86 06/24/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211617018
Principal investigator 1 Roche Products Limited $436.86 06/24/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211617114
Principal investigator 1 Roche Products Limited $436.86 06/24/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211617119
Principal investigator 1 Genentech, Inc. $2,086.00 06/03/2025 Non-covered Recipient Entity
INTERSPOND LLC
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211617175
Principal investigator 1 Novartis Pharmaceuticals Corporation $18,779.44 05/27/2025 Non-covered Recipient Entity
NEURO MEDIAL CLINIC OF CENTRAL LOUISIANA
A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light No dispute reported 06/30/2026 1190308208
Principal investigator 1 Genentech, Inc. $28,372.00 05/23/2025 Non-covered Recipient Entity
INTERSPOND LLC
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211617178
Principal investigator 1 Genentech, Inc. $1,697.00 05/02/2025 Non-covered Recipient Entity
INTERSPOND LLC
OCARINA I No dispute reported 06/30/2026 1211617215
Principal investigator 1 Celgene Corporation $3,300.00 04/09/2025 Non-covered Recipient Entity
Investigator Research Network Llc
A PHASE 3B, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE IMMUNOLOGICAL RESPONSE TO, AND THE SAFETY OF, THREE PARENTERALLY ADMINISTERED VACCINES IN SUBJECTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS WHO RECEIVE ORAL OZANIMOD, NON-PEGYLATED INTERFERON-, OR NO DISEASE MODIFYING THERAPY No dispute reported 06/30/2026 1222306577
Principal investigator 1 GENZYME CORPORATION $13,638.00 04/02/2025 Non-covered Recipient Entity
Investigator Research Network Llc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226083316
Principal investigator 1 GENZYME CORPORATION $1,700.00 03/24/2025 Non-covered Recipient Entity
Investigator Research Network Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226083312
Principal investigator 1 Genentech, Inc. $5,150.00 03/20/2025 Non-covered Recipient Entity
INTERSPOND LLC
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211617201
Principal investigator 1 Genentech, Inc. $4,207.00 03/14/2025 Non-covered Recipient Entity
INTERSPOND LLC
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211617197
Principal investigator 1 Genentech, Inc. $1,697.00 03/14/2025 Non-covered Recipient Entity
INTERSPOND LLC
OCARINA I No dispute reported 06/30/2026 1211617211
Principal investigator 1 Celgene Corporation $18,008.50 02/28/2025 Non-covered Recipient Entity
Interspond, Llc
A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated with Ozanimod (RPC-1063) No dispute reported 06/30/2026 1222306905
Principal investigator 1 Novartis Pharmaceuticals Corporation $18,138.21 02/21/2025 Non-covered Recipient Entity
INTERSPOND LLC
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1190299606
Principal investigator 1 Genentech, Inc. $34,075.00 02/20/2025 Non-covered Recipient Entity
INTERSPOND LLC
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211617194
Principal investigator 1 Novartis Pharmaceuticals Corporation $99,611.27 02/19/2025 Non-covered Recipient Entity
NEURO MEDIAL CLINIC OF CENTRAL LOUISIANA
A Pilot Open-Label, Randomized, Multi-Center, Parall el-Arm, of Acute vs Delay Ofatumumab Treatment d uring an Acute Multiple Sclerosis Relapse No dispute reported 06/30/2026 1190308206
Principal investigator 1 Genentech, Inc. $1,910.00 01/10/2025 Non-covered Recipient Entity
INTERSPOND LLC
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211617182
Principal investigator 1 Novartis Pharmaceuticals Corporation $166,822.95 01/01/2025 Non-covered Recipient Entity
NEURO MEDICAL CLINIC OF CENTRAL LOUISIANA
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1190307581